Moolec Science (MLECW) Retained Earnings (2022 - 2025)
Moolec Science (MLECW) posted Retained Earnings of -$44.6 million for Q4 2025, up 60.13% sequentially from -$111.8 million in Q2 2025, and up 36.58% YoY from -$32.6 million in Q4 2024.
Moolec Science (MLECW) Retained Earnings (2022 - 2025) Analysis & Trends
Moolec Science has reported Retained Earnings for 4 years, with the latest figure at -$44.6 million in Q4 2025.
- Quarterly Retained Earnings rose 36.58% year-over-year to -$44.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$44.6 million (up 36.58% YoY) and the FY2025 annual result came in at -$111.8 million, down 9882.57% from the prior year.
- Retained Earnings rose to -$44.6 million in Q4 2025 per MLECW's latest filing, from -$111.8 million in the prior quarter.
- Over five years, Retained Earnings peaked at $1.1 million in Q2 2024 and troughed at -$111.8 million in Q2 2025.
- A 4-year average of -$54.7 million and a median of -$59.4 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings soared 101.95% in 2024, then slumped 9882.57% in 2025.
- Over 4 years, Retained Earnings stood at -$55.5 million in 2022, then retreated by 11.67% to -$62.0 million in 2023, then fell by 13.36% to -$70.3 million in 2024, then jumped by 36.58% to -$44.6 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$44.6 million, -$111.8 million, and -$70.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -44.57 Mn |
| Jun 30, 2025 | -111.79 Mn |
| Dec 31, 2024 | -70.28 Mn |
| Sep 30, 2024 | -67.85 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | -63.40 Mn |
| Dec 31, 2023 | -62.00 Mn |
| Sep 30, 2023 | -60.21 Mn |
| Jun 30, 2023 | -58.62 Mn |
| Mar 31, 2023 | -55.88 Mn |
| Dec 31, 2022 | -55.52 Mn |
| Jun 30, 2022 | -6.83 Mn |